NCT02336061

Brief Summary

The purpose of this study is to evaluate of gender differences on the psychosocial and economic impact in patients with advanced non-small cell lung cancer.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
344

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2015

Typical duration for all trials

Geographic Reach
1 country

18 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 3, 2014

Completed
1 month until next milestone

First Posted

Study publicly available on registry

January 12, 2015

Completed
22 days until next milestone

Study Start

First participant enrolled

February 3, 2015

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2017

Completed
Last Updated

December 15, 2017

Status Verified

December 1, 2017

Enrollment Period

2.8 years

First QC Date

December 3, 2014

Last Update Submit

December 14, 2017

Conditions

Outcome Measures

Primary Outcomes (2)

  • Psychosocial impact (Test Family APGAR, Partner Test and adapted Duke-UNC-11 Scale)

    The procedures for assessing psychosocial impact are: Test Family APGAR, Partner Test and adapted Duke-UNC-11 Scale. These tests will be performed by the investigator at visit baseline, visit 2 visit 3 and visit 4, according to the site's standard practice until patient death or for up to 24 months from the time of inclusion.

    2 years

  • Economic impact (employment status, working hours, income range, public assistance, family support ...)

    The procedures for assessing economic impact are some specific economic variables (employment status, working hours, income range, public assistance, family support ...)

    2 years

Secondary Outcomes (2)

  • Influence of treatment (reatment received, treatment received, tumour ssessment, Medical history, including history of smoking, ECOG performance status, associated medical conditions and prior treatments administered (surgery, adjuvant treatment).

    2 years

  • Psychosocial and economic impact on the primary caregiver (Zarit Caregiver Burden Questionnaire and Test assessing the economic impact)

    2 years

Study Arms (2)

male

It will be stratified based on biological sex, age and smoking to guarantee homogeneity between the cohorts.

Behavioral: Evaluation of gender differences on the psychosocial and economic impact.

female

It will be stratified based on biological sex, age and smoking to guarantee homogeneity between the cohorts.

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Approximately 1250 patients over 18 years of age (approximately 50% men/women), with metastatic NSCLC, who are going to commence first-line treatment and who have a life expectancy of over three months will be included. They will be distributed into two cohorts (men and women) at 50% and will be distributed by age group and smoking status to facilitate the homogeneity between the two cohorts.

You may qualify if:

  • Patients diagnosed with stage IV NSCLC who are going to commence first line treatment
  • Patients over the age of 18
  • ECOG 0-3
  • Patients who have granted their informed consent, preferably in writing, but otherwise, verbal with witnesses who are independent of the research team
  • Life expectancy of over three months
  • Speak fluent Spanish, in order to be able to complete the study questionnaires
  • Patients able to read and write with no problems

You may not qualify if:

  • Previous systemic treatment for metastatic NSCLC. The administration of neoadjuvant or adjuvant radiotherapy and/or chemotherapy is permitted provided it was completed major or equal 6 months prior
  • Dementia or a significantly altered mental state that could affect comprehension or the ability to grant informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (18)

Hospital Universitario Son Espases

Palma de Mallorca, Balearic Islands, 07010, Spain

Location

Hospital de Son Llàtzer

Palma de Mallorca, Balearic Islands, 07198, Spain

Location

Hospital German Trias i Pujol

Badalona, Barcelona, 08916, Spain

Location

Hospital Provincial de Castellón

Castellon, Castellón, 12006, Spain

Location

Hospital Universitario Puerta de Hierro

Majadahonda, Madrid, 28222, Spain

Location

Complexo Hospitalario Universitario A Coruña

A Coruña, 15006, Spain

Location

Hospital de la Santa Creu i Sant Pau

Barcelona, 08026, Spain

Location

Hospital Universitario Vall d'Hebron

Barcelona, 08035, Spain

Location

Hospital Clínic de Barcelona

Barcelona, 08036, Spain

Location

Hospital Universitario Ramón y Cajal

Madrid, 28034, Spain

Location

Fundación Jiménez Díaz

Madrid, 28040, Spain

Location

Hospital Clínico Universitario San Carlos

Madrid, 28040, Spain

Location

Hospital Universitario La Paz

Madrid, 28046, Spain

Location

Hospital General Universitario de Valencia

Valencia, 46014, Spain

Location

Hospital Arnau de Villanova

Valencia, 46015, Spain

Location

Hospital La Fe

Valencia, 46026, Spain

Location

Hospital Clínico Universitario Lozano Blesa

Zaragoza, 50009, Spain

Location

Hospital Universitario Miguel Servet

Zaragoza, 50009, Spain

Location

Related Publications (1)

  • Vinolas NN, Garcia-Campelo R, Majem M, Carcereny E, Isla D, Gonzalez-Larriba JL, Coves J, De-Castro J, Domine M, Lianes P, Artal A, Remon J, Felip E, Garrido P. Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study. BMC Psychol. 2020 Nov 23;8(1):123. doi: 10.1186/s40359-020-00489-z.

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • María Rosario García, MD

    Complejo Hospitalario A Coruña

    STUDY CHAIR
  • Pilar Garrido, MD

    Hospital Universitario Ramón y Cajal

    STUDY CHAIR
  • Nuria Viñolas, MD

    Hospital Clinic of Barcelona

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 3, 2014

First Posted

January 12, 2015

Study Start

February 3, 2015

Primary Completion

November 30, 2017

Study Completion

November 30, 2017

Last Updated

December 15, 2017

Record last verified: 2017-12

Locations